AVASTIN

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, United Kingdom, United States, South Africa

Active ingredients

The drug AVASTIN contains one active pharmaceutical ingredient (API):

1 Bevacizumab UNII 2S9ZZM9Q9V - BEVACIZUMAB

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth. Read about Bevacizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AVASTIN Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FG01	Bevacizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 529207901139218, 529207902151211
Country: CA	Health Products and Food Branch	Identifier(s): 02270994
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 28761-02-09
Country: EE	Ravimiamet	Identifier(s): 1179952, 1187973
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 04300001, 04300002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 019445, 019781
Country: FR	Base de données publique des médicaments	Identifier(s): 60391646
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 91527, 91530
Country: HK	Department of Health Drug Office	Identifier(s): 56637, 56638, 59449, 59450
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4932, 4933
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291413A1022, 4291413A2029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1027602, 1027603
Country: NL	Z-Index G-Standaard	Identifier(s): 15023753
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 76910, 76929
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11531
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100129386
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64373001, W64373002
Country: SG	Health Sciences Authority	Identifier(s): 13065P, 14097P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 6993191H, 6993192H
Country: US	FDA, National Drug Code	Identifier(s): 50242-060, 50242-061
Country: ZA	Health Products Regulatory Authority	Identifier(s): A39/26/0314, A39/26/0315